Skip to main content

Advertisement

SpringerLink
Log in

Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

EGFR tyrosine-kinase inhibitors (TKIs) are used as targeted therapeutics for the treatment of advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations. EGFR C797S is common causes of acquired resistance to third-generation TKIs. There is wide-spread opinion that resistance-conferring mutation present even in a small proportion of cancer cells before the start of therapy could potentially predict poor response to a targeted drug. In our study, we tested whether C797S can be found in previously untreated NSCLCs. We analyzed DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue sections of 470 lung adenocarcinoma patients, including 235 samples with activating EGFR mutations. Screening was performed using highly sensitive droplet digital PCR assay. No tumor samples with baseline C797S were identified. C797S does not occur in TKI-naïve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Metro G (2018) EGFR targeted therapy for lung cancer: are we almost there? Transl Lung Cancer Res 7:S142–S145. https://doi.org/10.21037/tlcr.2018.03.11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bollinger MK, Agnew AS, Mascara GP (2018) Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract 24:379–388. https://doi.org/10.1177/1078155217712401

    Article  CAS  PubMed  Google Scholar 

  3. Lu X, Yu L, Zhang Z, Ren X, Smaill JB, Ding K (2018) Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC: current developments in medicinal chemistry. Med Res Rev 38:1550–1581. https://doi.org/10.1002/med.21488

    Article  CAS  PubMed  Google Scholar 

  4. Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11:473–481. https://doi.org/10.1038/nrclinonc.2014.104

    Article  CAS  PubMed  Google Scholar 

  5. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators (2018) Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer. N Engl J Med 378:113–125. https://doi.org/10.1056/NEJMoa1713137

    Article  CAS  PubMed  Google Scholar 

  6. Walter AO, Sjin RTT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 3:1404–1415. https://doi.org/10.1158/2159-8290.CD-13-0314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kim ES (2016) Olmutinib: first global approval. Drugs 76:1153–1157. https://doi.org/10.1007/s40265-016-0606-z

    Article  CAS  PubMed  Google Scholar 

  8. Lelais G, Epple R, Marsilje TH, Long YO, McNeill M, Chen B, Lu W, Anumolu J, Badiger S, Bursulaya B, DiDonato M, Fong R, Juarez J, Li J, Manuia M, Mason DE, Gordon P, Groessl T, Johnson K, Jia Y, Kasibhatla S, Li C, Isbell J, Spraggon G, Bender S, Michellys PY (2016) Discovery of ( R , E )- N -(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 H -benzo[ d ]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers. J Med Chem 59:6671–6689. https://doi.org/10.1021/acs.jmedchem.5b01985

    Article  CAS  PubMed  Google Scholar 

  9. Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR (2017) A phase I, dose escalation study of oral ASP8273 in patients with non–small cell lung cancers with epidermal growth factor receptor mutations. Clin Cancer Res 23:7467–7473. https://doi.org/10.1158/1078-0432.CCR-17-1447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Xu X (2015) Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance. Chin J Cancer 34:27. https://doi.org/10.1186/s40880-015-0029-3

    Article  CAS  PubMed Central  Google Scholar 

  11. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21:560–562. https://doi.org/10.1038/nm.3854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chen L, Fu W, Zheng L, Liu Z, Liang G (2018) Recent Progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. J Med Chem 61:4290–4300. https://doi.org/10.1021/acs.jmedchem.7b01310

    Article  CAS  PubMed  Google Scholar 

  13. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, Kiura K, Shimizu N, Date H (2006) Presence of Epidermal Growth Factor Receptor gene T790M mutation as a minor clone in non–small cell lung cancer. Cancer Res 66:7854–7858. https://doi.org/10.1158/0008-5472.CAN-06-1951

    Article  CAS  PubMed  Google Scholar 

  14. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ (2014) Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25:423–428. https://doi.org/10.1093/annonc/mdt573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315–1316. https://doi.org/10.1038/ng1671

    Article  CAS  PubMed  Google Scholar 

  16. Gazdar A, Robinson L, Oliver D, Xing C, Travis WD, Soh J, Toyooka S, Watumull L, Xie Y, Kernstine K, Schiller JH (2014) Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol 9:456–463. https://doi.org/10.1097/JTO.0000000000000130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Oxnard GR, Heng JC, Root EJ, Rainville IR, Sable-Hunt AL, Shane-Carson KP, Carbone DP, Wiesner GL, Garber JE (2015) Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR. J Clin Oncol 33:1505. https://doi.org/10.1200/jco.2015.33.15_suppl.1505

    Article  Google Scholar 

  18. Armbruster DA, Pry T (2008) Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29(Suppl 1):S49–S52 https://doi.org/citeulike-article-id:3416410. Accessed 29 Aug 2008.

  19. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, Hudoyo A, He Y, Zhang YP, Wang MZ, Liu CY, Ratcliffe M, McCormack R, Reck M (2017) EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study. Lung Cancer 113:37–44. https://doi.org/10.1016/j.lungcan.2017.08.021

    Article  PubMed  Google Scholar 

  20. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA (2018) Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to Osimertinib. JAMA Oncol 4:1527–1534. https://doi.org/10.1001/jamaoncol.2018.2969

    Article  PubMed  Google Scholar 

  21. Nagano T, Tachihara M, Nishimura Y (2018) Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells 7:212. https://doi.org/10.3390/cells7110212

    Article  CAS  PubMed Central  Google Scholar 

  22. Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, Liu Y, Wang Y, Zhou C (2018) Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor Osimertinib in non-small cell lung cancer patients. Clin Cancer Res 24:3097–3107. https://doi.org/10.1158/1078-0432.CCR-17-2310

    Article  CAS  PubMed  Google Scholar 

  23. Ho C-C, Liao W-Y, Lin C-A, Shih JY, Yu CJ, Chih-Hsin Yang J (2017) Acquired BRAF V600E mutation as resistant mechanism after treatment with Osimertinib. J Thorac Oncol 12:567–572. https://doi.org/10.1016/j.jtho.2016.11.2231

    Article  PubMed  Google Scholar 

  24. S-HI O, Cui J, Schrock AB et al (2017) Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer 108:228–231. https://doi.org/10.1016/j.lungcan.2017.04.003

    Article  Google Scholar 

  25. Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negrão MV, Reis LFL, Katz A, Camargo AA (2017) Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer 108:238–241. https://doi.org/10.1016/j.lungcan.2017.04.004

    Article  PubMed  Google Scholar 

  26. van Noesel J, van der Ven WH, van Os TAM, Kunst PWA, Weegenaar J, Reinten RJA, Kancha RK, Duyster J, van Noesel CJM (2013) Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol 31:e161–e164. https://doi.org/10.1200/JCO.2012.42.1586

    Article  CAS  PubMed  Google Scholar 

  27. Ruan Z, Kannan N (2015) Mechanistic insights into R776H mediated activation of epidermal growth factor receptor kinase. Biochemistry 54:4216–4225. https://doi.org/10.1021/acs.biochem.5b00444

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The work was partially supported by Russian State funded budget project #АААА-А17-117020210025-5 to ICBFM SB RAS.

Author information

Authors and Affiliations

  1. Laboratory of Pharmacogenomics, Institute of Chemical Biology and Fundamental Medicine, 8 Lavrentiev Avenue, Novosibirsk, 630090, Russia

    Igor P. Oscorbin & Maxim L. Filipenko

  2. Novosibirsk State University, 2 Pirogova Street, Novosibirsk, 630090, Russia

    Igor P. Oscorbin, Alexandra S. Shadrina & Maxim L. Filipenko

  3. Institute of Cytology and Genetics, 10 Lavrentiev Avenue, Novosibirsk, 630090, Russia

    Alexandra S. Shadrina, Vadim V. Kozlov & Vladimir E. Voitsitsky

  4. Novosibirsk Regional Clinical Oncological Center, 2 Plakhotnogo Street, Novosibirsk, 630108, Russia

    Vadim V. Kozlov & Vladimir E. Voitsitsky

Authors
  1. Igor P. Oscorbin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandra S. Shadrina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vadim V. Kozlov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladimir E. Voitsitsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maxim L. Filipenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Igor P. Oscorbin.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oscorbin, I.P., Shadrina, A.S., Kozlov, V.V. et al. Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues. Pathol. Oncol. Res. 26, 1229–1234 (2020). https://doi.org/10.1007/s12253-019-00683-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-019-00683-4

Keywords

Search

Navigation